bekhterevОбозрение психиатрии и медицинской психологии имени В.М.БехтереваV.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY2313-70532713-055XV. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH10.31363/2313-7053-2019-4-1-26-27bekhterev-295Research ArticleНАУЧНО-ИССЛЕДОВАТЕЛЬСКИЕ РАБОТЫRESEARCH PAPERSГенетические предикторы терапевтического ответа на препараты литияGenetic Predictors of Lithium ResponseХейлброннерУ.HeilbronnerU.Институт психиатрической геномики и феномики, Университетский госпиталь, Мюнхенский университет Людвига-МаксимилианаГерманияInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU MunichGermany20190612201904-12627Copyright © Хейлброннер У., 20192019Хейлброннер У.Heilbronner U.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.bekhterevreview.com/jour/article/view/295

В настоящее время литий остается фармакологическим препаратом первой линии для  лечения биполярного расстройства (БАР). Тем не менее, ответ на лечение неоднороден, что объясняется несколькими линиями доказательств вовлечения генетических факторов. К сожалению, ни исследования генов-кандидатов, основанные на гипотезах, ни первичные полногеномные исследования (GWAS) не были успешны в определении генетических  факторов гетерогенности ответа. Вероятно, это связано с низкой статистической мощностью и различными подходами к оценке фенотипа. Недавно Международный консорциум по фармакогенетике препаратов лития (ConLiGen) провел GWAS и идентифицировал четыре однонуклеотидных полиморфизма (SNP), опосредующих ответ на литий и расположенных в генах двух длинных некодирующих РНК. Этот успех был возможен только благодаря международному сотрудничеству и использованию единой шкалы оценки ответа на терапию литием. Полученные данные нуждаются в дальнейшей репликации.

Lithium remains a first-line pharmacological treatment of bipolar disorder (BD). However, treatment response is heterogeneous, with several lines of evidence implicating genetic factors. Unfortunately, neither hypothesis-driven approaches nor initial genome-wide association studies (GWAS) were successful in identifying genetic drivers of response heterogeneity, probably due to low statistical power and different phenotype measurements. Recently, a GWAS of the Consortium of Lithium Genetics (ConLiGen) has identified four single nucleotide polymorphisms (SNPs) mediating response to lithium, located in genes for two long non-coding RNAs. This success was only possible by international collaboration and the use of an established lithium response scale. The findings await further replication.

биполярное аффективное расстройствотерапияGWASтерапевтический ответшкала ALDАдлинная некодирующая РНКbipolar disordermedicationGWASresponseALDA scalelong non-coding RNAReferencesAlda M., Manchia M. Personalized management of bipolar disorder. Neuroscience Lettersю 2018;669:3 – 9. https://doi.org/10.1016/j.neulet.2017.12.005Alda M., Manchia M. Personalized management of bipolar disorder. Neuroscience Lettersю 2018;669:3 – 9. https://doi.org/10.1016/j.neulet.2017.12.005Garnham J., Munro A., Slaney C., Macdougall M., Passmore M., Duffy A., Alda M. Prophylactic treatment response in bipolar disorder: Results of a naturalistic observation study. Journal of Affective Disorders. 2007;104(1–3):185–190. https://doi. org/10.1016/j.jad.2007.03.003Garnham J., Munro A., Slaney C., Macdougall M., Passmore M., Duffy A., Alda M. Prophylactic treatment response in bipolar disorder: Results of a naturalistic observation study. Journal of Affective Disorders. 2007;104(1–3):185–190. https://doi. org/10.1016/j.jad.2007.03.003Grof P., Duffy A., Cavazzoni P., Grof E., Garnham J., MacDougall M., Alda M. Is response to prophylactic lithium a familial trait? The Journal of Clinical Psychiatry. 2002;63(10):942–947. https:// doi.org/10.4088/jcp.v63n1013Grof P., Duffy A., Cavazzoni P., Grof E., Garnham J., MacDougall M., Alda M. Is response to prophylactic lithium a familial trait? The Journal of Clinical Psychiatry. 2002;63(10):942–947. https:// doi.org/10.4088/jcp.v63n1013Hou L., Heilbronner U., Degenhardt F., Adli M., Akiyama K., Akula N., Schulze, T. G. Genetic variants associated with response to lithium treatment in bipolar disorder: A genome-wide association study. The Lancet. 2016;387(10023):1085–1093. https://doi.org/10.1016/S0140-6736(16)00143-4Hou L., Heilbronner U., Degenhardt F., Adli M., Akiyama K., Akula N., Schulze, T. G. Genetic variants associated with response to lithium treatment in bipolar disorder: A genome-wide association study. The Lancet. 2016;387(10023):1085–1093. https://doi.org/10.1016/S0140-6736(16)00143-4Papiol S., Schulze T. G., Alda M. Genetics of Lithium Response in Bipolar Disorder. Pharmacopsychiatry. 2018;51(5):206–211. https://doi. org/10.1055/a-0590-4992Papiol S., Schulze T. G., Alda M. Genetics of Lithium Response in Bipolar Disorder. Pharmacopsychiatry. 2018;51(5):206–211. https://doi. org/10.1055/a-0590-4992Perlis R.H., Smoller J.W., Ferreira M.A.R., McQuillin A., Bass N., Lawrence J., Purcell S. A genomewide association study of response to lithium for prevention of recurrence in bipolardisorder. The American Journal of Psychiatry. 2009;166(6):718–725. https://doi.org/10.1176/appi. ajp.2009.08111633Perlis R.H., Smoller J.W., Ferreira M.A.R., McQuillin A., Bass N., Lawrence J., Purcell S. A genomewide association study of response to lithium for prevention of recurrence in bipolardisorder. The American Journal of Psychiatry. 2009;166(6):718–725. https://doi.org/10.1176/appi. ajp.2009.08111633Pisanu C., Heilbronner U., Squassina A. The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine. Mol Diagn Ther. 2018;22(4):409–420. https://doi.org/10.1007/ s40291-018-0335-yPisanu C., Heilbronner U., Squassina A. The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine. Mol Diagn Ther. 2018;22(4):409–420. https://doi.org/10.1007/ s40291-018-0335-ySchulze T.G., Alda M., Adli M., Akula N., Ardau R., Bui E. T., … McMahon, F.J. The International Consortium on Lithium Genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology. 2010;62(1):72–78. https://doi. org/10.1159/000314708Schulze T.G., Alda M., Adli M., Akula N., Ardau R., Bui E. T., … McMahon, F.J. The International Consortium on Lithium Genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology. 2010;62(1):72–78. https://doi. org/10.1159/000314708Song J., Bergen S. E., Di Florio A., Karlsson R., Charney A., Ruderfer D. M., Landén M. Genomewide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder. Molecular Psychiatry. 2017;22(8):1223. https://doi. org/10.1038/mp.2016.246Song J., Bergen S. E., Di Florio A., Karlsson R., Charney A., Ruderfer D. M., Landén M. Genomewide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder. Molecular Psychiatry. 2017;22(8):1223. https://doi. org/10.1038/mp.2016.246Squassina A., Manchia M., Borg J., Congiu D., Costa M., Georgitsi M., Patrinos G.P. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics. 2011;12(11):1559–1569. https://doi.org/10.2217/ pgs.11.102Squassina A., Manchia M., Borg J., Congiu D., Costa M., Georgitsi M., Patrinos G.P. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics. 2011;12(11):1559–1569. https://doi.org/10.2217/ pgs.11.102

The authors declare that there are no conflicts of interest present.